Suppr超能文献

BR38,一种新型超声血池造影剂。

BR38, a new ultrasound blood pool agent.

机构信息

Bracco Suisse SA, Geneva, Switzerland.

出版信息

Invest Radiol. 2011 Aug;46(8):486-94. doi: 10.1097/RLI.0b013e318217b821.

Abstract

OBJECTIVE

: To evaluate BR38, a new microbubble-based blood pool agent for contrast-enhanced ultrasound imaging.

MATERIALS AND METHODS

: The size characteristics of BR38 microbubbles were measured by Coulter counting. The backscatter and attenuation coefficients were determined as a function of frequency. Additional measurements included the surface charge, osmolality, viscosity, and resistance to hydrostatic pressure. Extensive pharmacological and toxicological studies were conducted on the final formulation in rats and dogs. The blood levels and elimination of the gaseous component C4F10 were determined in the rabbit. Contrast-enhanced echographic examinations were performed in pigs focusing on the myocardium and the liver. Finally, safety testing and preliminary imaging experiments were performed in a Phase I clinical study in human volunteers.

RESULTS

: BR38 suspensions are isotonic, nonviscous, and show a high resistance to hydrostatic pressure. Their backscatter coefficient is high at ≥ 2 MHz and attenuation shows a maximum at 4 MHz, slowly decreasing at higher frequencies. The no adverse effect levels of 1 μL/kg (rats) and 5 μL/kg (dogs) expressed as microbubble gas volume, observed in repeated toxicology studies, correspond to 50 and 250 times the expected imaging dose in human beings (0.02 μL/kg), respectively. No effects on cardiovascular and respiratory parameters were observed in rats and dogs. C4F10 is eliminated within minutes from blood and excreted in expired air. Imaging experiments showed strong and persistent enhancement of the myocardium and the liver. A late phase was observed in the liver, in animals and in human volunteers. No serious adverse events and no significant changes in vital signs, electrocardiographs, and laboratory tests were observed in Phase I human volunteers.

CONCLUSIONS

: BR38 shows a very good safety profile. It is characterized by a long persistence and low shadowing. BR38 is a promising ultrasound blood pool agent for noncardiac and cardiac applications including myocardial perfusion imaging.

摘要

目的

评估 BR38,一种新的基于微泡的血池造影剂,用于对比增强超声成像。

材料与方法

通过库尔特计数测量 BR38 微泡的大小特征。测定背向散射和衰减系数作为频率的函数。其他测量包括表面电荷、渗透压、粘度和耐静压。在大鼠和犬中对最终配方进行了广泛的药理学和毒理学研究。在兔中测定气态成分 C4F10 的血水平和消除。在猪中进行对比增强超声检查,重点是心肌和肝脏。最后,在人体志愿者的 I 期临床研究中进行了安全性测试和初步成像实验。

结果

BR38 混悬剂为等渗、非粘性,并具有较高的耐静压能力。其背向散射系数在≥2MHz 时较高,在 4MHz 时衰减达到最大值,在较高频率时缓慢下降。在重复毒理学研究中观察到 1μL/kg(大鼠)和 5μL/kg(犬)的无不良影响水平(以微泡气体体积表示),分别相当于人体预期成像剂量的 50 倍和 250 倍(0.02μL/kg)。在大鼠和犬中未观察到心血管和呼吸参数的影响。C4F10 在几分钟内从血液中消除,并从呼出空气中排出。成像实验显示心肌和肝脏的强烈和持久增强。在动物和人体志愿者中观察到肝脏的后期阶段。在 I 期人体志愿者中未观察到严重不良事件和生命体征、心电图和实验室检查的显著变化。

结论

BR38 具有非常好的安全性。它的特点是持久性长,阴影低。BR38 是一种很有前途的超声血池造影剂,可用于非心脏和心脏应用,包括心肌灌注成像。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验